RE:RE:RE:RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...four, watch out trussel got banned from the scam board for agreeing with me...re. execution most trials of any size have non-compliance issues and again the failure rests with RVX leadership IMO..
..back to the gong show...IMO it is very "odd" that RVX did a major, major left turn revision in a left turn revisions trial...its like back to PII just with a different primary outcome...and what of all the trashtalking RVX did post PII re. the failure of lipitor-208...very odd and again to me goes to the issue of competence (PS imo the regulators required it to be included)
...re. FDA "approval" for the PIII IMO if RVX don't get formal FDA approval to the PIII it will not get marketing approval...on the too funny list, i am back reviewing earlier expert reports on approval failures in the FDA and this shows up a common cause for failure to gain marketing approval (drug companies who just don't listen to FDA communications)...and Europe and China amount to a hill of beans in comparison to FDA marketing approval.
..on an interesting diversion, do you know of any CDN baby biotechs that were successful with the founder as CEO???? is that list more than 5 if that??? IMO major problems are a) lack of successful regulatory experience (how many therapies have they ever brought to market) b) self-interest, entitlement and enrichment over the company mission and responsibility to shareholders...so for instance, RVX Board guy leaves and starts ESPR (boom nuff said he shoulda been offered anything to become CEO and CoB of RVX i wonder what prevented that)